Patients with mHNPC (n = 8) | Patients with mCRPC (n = 11) | |
---|---|---|
Variables at initial diagnosis of prostate cancer | ||
Median prostate-specific antigen (range), ng/mL | 910 (98–8900) | 232 (6–4271) |
Biopsy Gleason scores, n (%) | ||
≤ 7 | 0 (0.0%) | 2 (18.2%) |
8–10 | 5 (62.5%) | 9 (81.8%) |
Unknown | 3 (37.5%) | 0 (0.0%) |
Extent of disease on bone scan | ||
0 | 0 (0.0%) | 4 (36.4%) |
1 | 2 (25.0%) | 2 (18.2%) |
2 | 1 (12.5%) | 1 (9.1%) |
3 | 1 (12.5%) | 1 (9.1%) |
4 | 0 (0.0%) | 0 (0.0%) |
Unknown | 4 (50.0%) | 3 (27.3%) |
Variables at decompression surgery | ||
Median age (range), years | 72 (62–78) | 65 (46–71) |
Median prostate-specific antigen (range), ng/mL | 910 (98–8900) | 67 (0.1–307) |
Lesion of decompression surgery, n (%) | ||
Cervical spine | 0 (0.0%) | 1 (9.1%) |
Cervical-thoracic spine | 0 (0.0%) | 2 (18.2%) |
Thoracic spine | 6 (75.0%) | 6 (54.5%) |
Thoracic-lumbar spine | 0 (0.0%) | 1 (9.1%) |
Lumbar spine | 2 (25.0%) | 1 (9.1%) |
Median time to decompression surgery from symptoms occurrence (range), days | 4 (0–8) | 2 (0–14) |
The use of bone-targeted agentsa, n (%) | 0 (0.0%) | 4 (36.3%) |